双能量CT检查多参数成像预测胰腺导管腺癌病理学分级的应用价值

Application value of dual‑energy CT multi‑parameter imaging in predicting the pathological grade of pancreatic ductal adenocarcinoma

  • 摘要:
    目的 探讨双能量CT检查多参数成像预测胰腺导管腺癌病理学分级的应用价值。
    方法 采用回顾性队列研究方法。收集2017年1月至2023年8月温州医科大学附属第五医院收治的147例胰腺导管腺癌患者的临床病理资料;男102例,女45例;年龄为(59±10)岁。患者均行术前双能量CT检查和术后组织病理学检查。147例患者采用分层随机抽样法按7∶3分为训练集103例和测试集44例。训练集用于构建预测模型,测试集用于验证预测模型效能。观察指标:(1)影响训练集胰腺导管腺癌患者病理学分级的因素分析。(2)胰腺导管腺癌病理学分级联合预测模型的构建与评价。正态分布的计量资料组间比较采用独立样本t检验;偏态分布的计量资料组间比较采用Mann‑Whitney U检验。计数资料组间比较采用χ²检验。单因素和多因素分析采用Logistic回归模型。模型的效能评估采用受试者工作特征(ROC)曲线分析,并计算曲线下面积(AUC)、准确度、灵敏度和特异度,使用Delong检验分析模型效能。Hosmer⁃Lemeshow检验校准曲线和决策曲线分别用于评价列线图的一致性和临床应用价值。
    结果 (1)影响训练集胰腺导管腺癌患者病理学分级的因素分析。多因素分析结果显示:肿瘤囊变坏死、血管侵犯、静脉期标准化碘浓度(NIC)、静脉期有效原子序数(Zeff)、静脉期能谱曲线斜率(λHU)均是训练集胰腺导管腺癌患者病理学分级的独立影响因素(优势比=4.326、3.887、4.155、5.389、3.164,95%可信区间(CI)为1.167~16.033、1.111~13.592、1.707~10.113、1.284~22.613、1.247~8.028,P<0.05)。(2)胰腺导管腺癌病理学分级联合预测模型的构建与评价。根据多因素分析结果,纳入肿瘤囊变坏死、血管侵犯、静脉期NIC、静脉期Zeff和静脉期λHU构建临床‑影像学联合预测模型列线图。训练集中联合预测模型AUC为0.938(95%CI为0.896~0.981)、准确度为87.38%、灵敏度为89.74%、特异度为85.94%;测试集上述指标分别为0.893(95%CI为0.802~0.985)、84.09%、82.35%、85.19%。Delong检验结果显示:训练集和测试集AUC比较,差异无统计学意义(Z=0.343,P>0.05)。Hosmer‑Lemeshow检验结果显示:联合预测模型在训练集和测试集中的拟合度较好(χ²=3.042、7.545,P>0.05)。校准曲线结果显示:联合预测模型的预测能力良好。
    结论 双能量CT检查静脉期的多个参数可作为术前评估胰腺导管腺癌患者病理学分级的影像学标志物;建立临床‑影像学联合预测模型可有效预测胰腺导管腺癌的病理学分级。

     

    Abstract:
    Objective To investigate the application value of dual‑energy computer tomo-graphy (CT) multi‑parameter imaging in predicting the pathological grade of pancreatic ductal adeno-carcinoma (PDAC).
    Methods The retrospective cohort study was conducted. The clinicopatholo-gical data of 147 patients with PDAC who were admitted to The Fifth Affiliated Hospital of Wenzhou Medical University from January 2017 to August 2023 were collected. There were 102 males and 45 females, aged (59±10)years. All patients underwent preoperative dual-energy CT examination and postoperative histopathological examination. The 147 patients were divided into a training set of 103 cases and a test set of 44 cases by stratified random sampling at a ratio of 7∶3. The training set was used to construct the prediction model, and the test set was used to verify the effectiveness of prediction model. Observation indicators: (1) analysis of factors affecting the pathological grade of PDAC patients in the training set; (2) construction and evaluation of the fusion prediction model for pathological grade of PDAC. Comparison of measurement data with normal distribution between groups was conducted using the independent sample t test. Comparison of measurement data with skewed distribution between groups was conducted using the Mann‑Whitney U test. Comparison of count data between groups was conducted using the chi‑square test. Univariate and multivariate analyses were conducted using the Logistic regression model. The performance of the model was evaluated by receiver operating characteristic (ROC) curve, and the area under the curve (AUC), accuracy, sensitivity and specificity were calculated. The Delong test was used to analyze the effec-tiveness of model. The calibration curve and decision curve of Hosmer-Lemeshow test were used to evaluate the consistency and clinical application value of the nomogram, respectively.
    Results (1) Analysis of factors affecting the pathological grade of PDAC patients in the training set. Results of multivariate analysis showed that tumor cystic necrosis, vascular invasion, standardized iodine concentration (NIC) in venous phase, effective atomic number (Zeff) in venous phase, and energy spectrum curve slope (λHU) in venous phase were all independent factors affecting the pathological grade of PDAC patients in the training set (odds ratio=4.326, 3.887, 4.155, 5.389, 3.164, 95% confidence interval as 1.167-16.033, 1.111-13.592, 1.707-10.113, 1.284-22.613, 1.247-8.028, P<0.05). (2) Construction and evaluation of the fusion prediction model for pathological grade of PDAC. Accor-ding to the results of multivariate analysis, tumor cystic necrosis, vascular invasion, NIC in venous phase, Zeff in venous phase and λHU in venous phase were all included to construct the clinical-imaging fusion prediction nomogram model. The AUC, accuracy, sensitivity and specificity of the fusion prediction model in the training set were 0.938 (95% confidence interval as 0.896-0.981), 87.38%, 89.74% and 85.94%, respectively. The above indicators of the fusion prediction model in the test set were 0.893 (95% confidence interval as 0.802-0.985), 84.09%, 82.35% and 85.19%, respectively. Results of Delong test showed that there was no significant difference in AUC between the training set and the test set (Z=0.343, P>0.05). Results of Hosmer‑Lemeshow test showed that the fusion prediction model had a good fit in the training set and the test set (χ²=3.042, 7.545, P>0.05). Results of calibration curve showed that the predictive ability of the fusion prediction model was good.
    Conclusions Multiple parameters in venous phase of the dual‑energy CT can be used as imaging markers for preoperative evaluation of the pathological grade of patients with PDAC. Establishing a clinical‑imaging fusion prediction model can effectively predict the pathological grade of PDAC.

     

/

返回文章
返回